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INTRODUCTION 
The list of hepatitis viruses has been increasing over 
recent years. These viruses are members of diverse 
families and, consequently, have different properties. 
Hepatitis A virus (an R N A  virus similar to the 
Picornaviridae) and hepatitis E virus (an R N A  virus 
with some features of the Caliciviridae) are transmitted 
enterically and induce an acute hepatitis, which rarely 
becomes chronic. In contrast, hepatitis B virus (a DNA 
virus, Hepadnaviridae), hepatitis D virus (a defective 
KNA virus, dependent on hepatitis B virus for 
propagation in hepatocytes), and hepatitis C virus (an 
RNA virus, Flaviviridae) are transmitted mainly 
through blood and blood products, and cause chronic 
as well as acute hepatitis. The former can lead to 
cirrhosis and hepatocellular carcinoma. 
There are some patients (approximately 1&20%) 
with acute or chronic hepatitis who show no serologic 
markers of hepatitis A, B or C virus infection, and also 
have no evidence of infection with hepatitis D or E 
virus (non-A-E hepatitis). Evidence for further new 
‘hepatitis’ viruses has been reported in the hope of 
explaining these cases of non-A-E hepatitis [I ,2]. 
THE GB HEPATITIS VIRUSES AND 
HEPATITIS G VIRUS 
In 1967 Deinhardt et al [3] made the important 
observation that the serum from a surgeon (whose 
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initials were GB) with the retrospective diagnosis of 
non-A-E hepatitis induced hepatocellular injury in a 
primate (the tamarin). This report remained contro- 
versial until the recent application of molecular 
techniques. In 1995, two new flavi-like viruses, GB 
virus A and GB virus B (GBV-A and GBV-B), derived 
from tamarins inoculated with ‘GB agents’, were 
cloned and characterized [4]. 
The isolation of GBV-A and GBV-B has allowed 
the subsequent identification of a third new flavi-like 
virus-GB virus C (GBV-C) from human sera from 
patients with non-A-E hepatitis [5]. In 1996, Leary 
et a1 [l]  established the genomic sequence and 
organization of GBV-C. Independently, an R N A  virus, 
provisionally designated hepatitis G virus (HGV), was 
identified from the plasma of a patient with chronic 
hepatitis [6] .  The two viruses GBV-C and HGV were 
found to be closely related to each other. They have 
more than 90% and 95% homology at the nucleotide 
and amino acid levels, respectively [6]. This close 
similarity provides strong evidence that the two viruses 
are actually different isolates of the same virus. Since 
the nomenclature has not yet been decided, it should 
be designated provisionally as GBV-C/HGV [7]. GBV- 
A, GBV-B and GBV-C/HGV, together with HCV, are 
members of distinct viral groups in the Flaviviridae. 
Phylogenetic analysis of their genomic sequences 
showed that GBV-A, GBV-B and GBV-C/HGV are 
not genotypic variants of HCV [7-91. GBV-A and 
GBV-B seem to originate in tamarins and their 
genomes have not so far been detected in humans 
[9,10]. However, GBV-C/HGV has been considered 
to be a putative cause of non-A-E hepatitis. 
Molecular characterization of the GBV-C/HGV 
shows that it has a positive strand linear R N A  genome, 
approximately 10 kb in length, with a single large open 
reading frame that appears to encode the structural 
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proteins at  the 5’ end. The non-structural proteins 
NS2, NS3, NS4, NS5A and NSSB are located at the 
3’ end of the genome [1,6]. However, unlike in hep- 
atitis C virus, a typical core nucleoprotein seems to be 
either absent or defective in GBV-C/HGV [1,6,11,12]. 
The manner in which this absent or defective core 
protein influences the pathogenesis of any associated 
disease is unknown [13]. 
Isolates of GBV-C/HGV from different parts of 
the world show genetic heterogeneity [12,14,15]. 
Major genotypes 1 ,  2 and 3 exist and show a strong 
correlation with their geographic origin. Isolates of 
y p e  1, type 2 and type 3 were found exclusively in 
West Africa, the USA and Europe, and Asia, respec- 
tively [l6J. However, GBV-C/HGV seems to be less 
variable than HCV [I 71. The relatively limited genetic 
variations observed in GBV-C/HGV isolates may 
reflect a relatively low level of host selection pressure, 
and they are unlikely to display significant biological 
differences [ 181. 
DIAGNOSIS 
Up to now, no serologic tests have been available to 
monitor activity by GBV-C/HGV [9]. Mostly, diag- 
nosis currently depends upon the detection of viral 
RNA in serum by reverse transcription P C R  (RT- 
PCR [5,6]. A single pair or nested primers have been 
used to a m p l i ~  sequences from the non-structural 
regions NS3 and NS5A, and also from the 5’ non- 
coding region of the genome, which contains highly 
conserved domains [ 12,191. 
Recently, an enzyme-linked ininiunosorbent assay 
(ELISA) for detecting antibodies to a putative GBV- 
C/HGV envelope protein (anti-GBV-C/HGV E2) has 
been developed [20,21]. Whether this iinmunoassay 
will be useful in diagnosing infection with GBV- 
C/HGV, and what the clinical significance is of anti- 
GBV-C/HGV E2 antibody, have still to be determined 
[13,21,22]. 
PREVALENCE OF GBV-C/HGV INFECTION 
Persistent infection with GBV-C/HGV has been 
detected surprisingly frequently (0.9-2%) in volunteer 
blood donors from industrialized countries. Positives 
had a mild elevation of alanine aminotransferase (ALT), 
but at  least 50% did not show any evidence of liver 
disease [6,23-25]. Frequent contamination with GBV- 
U H G V  R N A  sequences in batches of immuno- 
globulin manufactured without specific viral inactiv- 
ation procedures has also been documented. Despite 
the extremely high level of contamination of these 
blood products by GBV-C/HGV sequences, their use 
was not associated with high rates ofpersistent infection 
in recipients [26-29]. 
Nevertheless, a specific group of patients appeared 
to be particularly at  risk of GBV-C/HGV infection. 
These included hemophiliacs, patients with solid organ 
transplants, patients on hemodialysis, intravenous drug 
users, and patients co-infected by other hepatitis 
viruses-HBV or HCV. Persistent GBV-C/HGV was 
observed in 4.5-1 9% of heniodialysis patients [30-321, 
20.9% of hemophiliacs [33) ,  and 33% of intravenous 
drug users [24]. In all these patients positive for GBV- 
C/HGV genomes, there was an absence of liver 
dysfunction. GBV-C/HGV can be transmitted by solid 
organ transplantation, and infection with this virus 
appears to be very frequent in these patients: 41.2-67% 
after liver transplantation [34,35). However, these 
results preclude definitive conclusions concerning the 
role of GBV-C/HGV in disease, because these positive 
transplant patients had no evidence of liver dysfunction 
GBV-C/HGV seems to co-infect or superinfect 
patients with other parenterally transmitted hepatitis 
viruses: hepatitis C (HCV) or hepatitis B (HBV). GBV- 
C/HGV R N A  was found in 10-1 6%) of patients with 
HCV infections, and in 5-15% of those with HBV 
infections [16,37]. A history of previous blood 
transfusion was found in 50-60’% of all GBV-C/HGV- 
positive subjects 1371. 
In most investigations, GBV-C/HGV RNA was 
found rarely (2-9941) in the seruni of patients with spor- 
adic acute or chronic non-A-E hepatitis [25,37-391. 
The percentage was higher (33%) if these patients had 
had a history of blood transfusion [40]. 
However, infection with GBV-C/HGV hay also 
been detected in a high proportion of patients with 
fulminant hepatitis [41-433. 
[361. 
TRANSMISSION OF GBV-C/HGV 
Transnllssion through blood transfusion or parenteral 
exposure has been well documented for GBV-C/HGV 
Both routes have been considered to be niajor modes 
of GBV-C/HGV transmission. This observation is sup- 
ported by the frequent coexistence of GBV-C/HGV 
and other parenterally acquired viruses such as HCV 
and HBV. 
Little is known about other modes of transmitting 
GBV-C/HGV. It seems likely that a sexual route exists 
1241. Reports have indicated that repeated exposure, 
including sexual and/or non-sexual intimate contact 
between spouses over time, niay be iniportant in 
transmitting GBV-C/HGV [22]. Mother-to-infant 
transmission of GBV-C/HGV, presumably occurring at 
birth, may cause persistent GBV-C/HGV viremia. 
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Analysis of GBV-C/HGV sequences confirms a strong 
genetic link between the viruses of the mother and 
those of the infected child [44]. 
RELATIONSHIP OF GBV-C/HGV INFECTION TO 
INDUCTION OF HEPATITIS-TREATMENT WITH 
INTERFERON 
Animal studies have shown that GBV-C/HGV can be 
transmitted experimentally to tamarins and chimpan- 
zees, but liver damage is seen only in tamarins. 
Persistent viremia in chimpanzees was not associated 
with abnormal liver tests or liver histology [45]. 
The published case series claims an association 
between GBV-C/HGV and acute or chronic non-A-E 
hepatitis in humans [6,23,46]. Clinically, this hepatitis 
is very mild and not usually associated with jaundice. 
Kecent prospective studies have shown that 75% of the 
recipients of transfusions positive for GBV-C/HGV 
show no biochemical evidence ofliver disease, and have 
normal ALT levels. The remaining 25% of the patients 
usually have slightly raised transaminase activity, but 
without any correlation with GBV-C/HGV R N A  
levels [47]. In general, the data available at the moment 
are insufficient to confirm that GBV-C/HGV is really 
a cause of non-A-E viral hepatitis. The investigations 
are hampered by the small number of patients with 
GBV-C/HGV infection alone. According to Alter et a1 
[39], the cause of acute non-A-E viral hepatitis in the 
USA remains unknown. Other authors [8,9] suggest 
that GBV-C/HGV may not be a hepatotropic agent 
initially and can induce hepatitis only under certain 
circumstances. 
GBV-C/HGV co-infection is frequent in patients 
with chronic hepatitis B or C infection, but it does not 
seem to play a significant pathogenic role [48]. In these 
cases GBV-C/HGV does not affect HCV replication, 
liver disease, or the response of HCV infection to 
interferon therapy [16,49]. GBV-C/HGV does not 
appear to play a role in liver disease, when associated 
with HCV, because neither the biochemical nor the 
histologic parameters of liver disease differ between 
GBV-C/HGV-positive and -negative patients. Detailed 
histopathologic evaluation of GBV-C/HGV infection 
in chronic hepatitis C patients or in chronic hepatitis C 
carriers shows that GBV-C/HGV affects neither the 
histopathologic severity nor other characteristics, thus 
suggesting a minor or absent role for GBV-C/HGV 
infection in chronic liver disease [50,51]. 
The role of GBV-C/HGV in fulminant hepatitis is 
more controversial. Yoshiba et a1 [41] found that three 
out of six cases with fulminant hepatitis of unknown 
etiology were positive for GBV-C/HGV RNA. They 
suggested that the virus might play an important role 
in fulminant or subfulminant hepatitis. Alternatively, 
the prevalence of GBV-C/HGV in fulminant hepatitis 
is low in Japan, but GBV-C/HGV may modift the 
clinical course of HCV-induced fulminant hepatitis 
[42]. Some authors also report a possible association 
between fulminant hepatic failure and a particular strain 
of GBV-C/HGV [43]. Other authors consider that 
detection of GBV-C/HGV in the serum of patients 
with fulminant hepatitis does not necessarily mean that 
GBV-C/HGV is a causal virus [52-541. Further studies 
are needed to elucidate the relationship between 
fulminant hepatitis and GBV-C/HGV. 
GBV-C/HGV is sensitive to interferon; after 
treatment with interferon, the concentration of GBV- 
C/HGV R N A  in serum decreases rapidly. However, 
after treatment is stopped it reverts to the initial levels 
[ 1 6,551. 
HUMORAL IMMUNE RESPONSE 
The prevalence of GBV-C/HGV KNA and anti-GBV- 
C/HGV envelope protein antibodies (anti-GBV- 
C/HGV E2) in Egyptian patients with chronic liver 
disease due to HCV infection has been studied [13]. 
Preliminary results show that the humoral immune 
response to E2 is associated with a loss of the detectable 
GBV-C/HGV viremia. A high prevalence of E2 
antibodies was found among those patients negative for 
GBV-C/HGV RNA,  and vice versa. This suggests that 
development of antibodies is associated with viral 
clearance. Hence, it is not known whether the presence 
of E2 antibodies protects against subsequent GBV- 
C/HGV infection. 
GBV-C/HGV REPLICATION AND VIRUS PERSISTENCE 
GBV-C/HGV replication has been established in 
human cultured cells: a T-cell line and a human 
hepatocyte line [56]. Whether GBV-C/HGV replicates 
in the liver in some or all patients remains to be 
established. Preliminary data suggest that it is present 
within peripheral blood lymphocytes [57]. GBV- 
C/HGV can persist for years in the blood of infected 
individuals without causing hepatitis [57]. The 
occurrence of viremia in the absence of raised liver 
aminotransferases suggests that an asymptomatic carrier 
state may exist [9]. It seems that GBV-C/HGV is 
epidemiologically similar, but pathogenically different 
from HCV. 
CONCLUSION 
The newly discovered GBV-C/HGV, belonging to the 
Flaviviridae, is responsible for a common, persistent, 
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transfusion-transmissible infection in humans. This fact 
raises the very important question of whether GBV- 
C/HGV is responsible for any disease and, if so, 
whether this disease involves the liver. Most of the 
evidence fails to implicate GBV-C/HGV as an 
etiologic agent of non-A-E hepatitis, and also indicates 
that GBV-C/HGV does not affect the clinical course 
in patients with HBV or HCV infection [39]. At the 
moment we cannot reach any definitive conclusions 
regarding the course and outcome of all individuals 
infected with GBV-C/HGV alone. More extensive 
studies are required before GBV-C/HGV can be 
regarded only as a passenger virus. The definite 
pathogenic roles of GBV-C/HGV have yet to be 
established [58]. Perhaps GBV-C/HGV, although 
related to HCV and belonging to the flaviviruses, is not 
truly a hepatitis virus, but rather a lymphotropic virus 
which only occasionally causes mild liver damage [8,9]. 
Nevertheless, whatever the real pathogenicity of 
GBV-C/HGV might be, the discovery of this novel 
virus transmitted by blood raises the problems of 
blood screening and prevention of transmission. It  is 
difficult at  present to screen blood donors for GBV- 
C/HGV routinely, and it is thus unclear what measures 
a blood bank should take regarding this virus [29]. 
Reliable serologic assays are needed for a deeper 
comprehension of the course of GBV-C/HGV 
infection 191. 
References 
1 .  
2. 
3.  
4. 
3. 
6. 
7 
X 
0 .  
10. 
11.  
Leary TP, MuerhoffAS, Sinions JN, et al. Sequence and genomic 
organization of GBV-C: a novel member of the Flaviviridae 
associated with human non-A-E hepatitis. J Med Virol 1996; 48: 
60-7. 
Alter HJ, Bradley 1lW. Non-A, non-B hepatitis unrelated to the 
hepatitis C virus (noIi-ABC). Seniin Liver Dis 1995; 15: 110-20. 
Deinhardt F, Holnies AW, Chpps KB, Popper H. Studies on the 
traiisniission of human viral hepatitis to marnioset monkeys. I. 
Transmission of disease, serial passages, and description of liver 
lesions. J Exp Med 1967; 125: 673-88. 
Simons JN, Pilot-Matias TJ, Leary TP, et al. Identification oftwo 
flavivirus-like genonies i i i  the GB hepatitis agent. Proc Natl 
Acad Sci USA 199.5; 92: 3401-5. 
Simons JN,  Leary TP, Dawson GJ, et al. Isolation ofnovel virus- 
like sequences associated with human hepatitis. Nature Med 
1995; 1: 564-9. 
Linnen J, Wages J, Zhange-Keck ZY, et al. Molecular cloning 
and disease association of hepatiti? G virus: a transfusioii- 
transiiiissible agent. Science 1996: 271: 505-8. 
Zuckernian AJ. Alphabet o f  hepatiti? viruses. Lancet 1996; 347: 
S.58-9 
Zuckerriian AJ. Hepatitis-how far down the alphabet? J Clin 
Path01 1997; -50: 1-2. 
Karayiannis 1’. Thoma, H.  Hepatitis G virus: identification, 
prevalence and unanswered questions. Gut 1997; 40: 29446. 
Schlauder GG, Pilot-Matias TJ, Gabriel GS, et al. Origin of GB- 
hepatitis viruses. Lancet 1995; 346: 447. 
Yaiiiaguchi K, Yagi S. Genetic organization of GBV-C. Nippon 
Kinsho 1997: 55: 535-9. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
25. 
26. 
27. 
‘ 8 .  
29. 
30. 
31. 
Muerhoff AS, Simons-JN, Lcary TP, et al. Sequence hetero- 
geneity within the j’-teriiunal region of the hepatitis GB virus 
C genome and evidence for genotypes. J Hepatol 1996; 25: 
379-84. 
Hassoba HM, Terrault NA, El-Goliary AM, et al. Antibody to 
GBV-C second envelope glycoprotein (anti-GBV-C E2): is it a 
marker for immunity? J Med Virol 1997; 53: 354460. 
Mukaide M, Mizokanii M, Orito E, et al. Three different GB 
virus C/hepatitis G virus genotypes. Phylogenetic analysis and a 
genotyping assay based on restriction fragment length polv- 
niorphism. FEBS Lett 1997: 407: 51-8. 
Viazov S, Kiffelmann M, Khoudyakov Y, Field? H,  Varenholz C. 
Koggendorf M. Genetic heterogeneity of hepatitis G virus 
isolates from different parts of the world. J Gen Virol 1997; 78: 
577-81. 
Pawlotsky JM, Roudot-Thoraval F, Muerhoff AS, et al. CB virus 
C (GBV-C) infection in patients with chronic hepatitis C. 
Influence on liver disease and on hepatitis virus behavior: effect 
of interferon alfa therapy. J Med Virol 1998; 54: 26-37. 
Pickering JM, Thornas HC,  Karayiannis P. Genetic diversity 
between hepatitis G virus isolates: analysis of nucleotide variation 
in  the NS-3 and putative ‘core’ peptide genes. J Gen Virol 1997: 
78: 53-60, 
Smith DB, Cuceanu N, Ilavidson F, et al. Discriiiiination of 
hepatitis G virus/GBV-C geographical variants by analysis of the 
5’ non-coding region. J Gen Virol 1997; 78: 1533-42. 
Ding M, Yuwen H,  Mitchell E Biswas K, Ndmibie OK. Fanhid 
M. Sequence characterization of the 5’ noncoding region o f  GB 
virus Clhepatitis G virus. Biocheni Biophvs Res Comniun 
1997; 231: 606-9. 
Tacke M, Kiyosawa K, Stark K, ct al. Detection of antibodies to 
a putative hepatitis G virus envelope protein. Lancet 1997; 349: 
318-20. 
Dille BJ, Surowy TK, Gutierrez KA, et dl.  ELISA for the 
detection of antibodies to the E2 protein of GBV-C. J Infect Dis 
1997; 175: 33-61. 
Kao JH, Liu CJ, Chen PJ, et al. Interspousal trdnsiiiissioii of GB 
virus-Whepatitis G virus: a comparison with hepatitis C virus 
J Med Virol 1997; 53: 348-53. 
Fiordalisi G, Zanella I, Mantero G, et al. High prevalence of GB 
virus C infection in a group of Italian patient5 with hepatitis of 
unknown etiology J Infect Dis 1996: 174: 181-3. 
Stark K, Bienzle U, Hess G, Engel AM. Hegenscheid B, Schluter 
V Detection of the hepatitis G virus genome among injecting 
drug users, homosexual and bisexual men, and blood donors. J 
Infect Dis 1996; 174: 1320-3. 
Nakatsuji Y, Shih JW, Taiiaka E, et al. Prevalence and disease 
association of hepatitis G virus infection in Japan. J Viral Hepat 
1996; 3: 307-16. 
Jarvis LM, Llavidson F, Haidey Jl< Yap PL.  Ludlaiii CA, 
Siiimonds 1’. Infection with hepatitis G virus among recipients 
of plasma products. Lancet 1996; 348. 1352-5. 
Berger A, Scharrer I. Uoerr HW, Hess C;, Weber B. Infection 
with hepatitis G viru\ in iInmunoglobulin recipient\. Lancet 
1997; 349: 207. 
Lefrere JJ, Kavera N, Corbi C ,  Mariotti M, Loiseau I! Infection 
with hepatitis G virus in iiimiunoglobulin recipients. Lancet 
1997; 349: 206. 
Kao JH,  Chen PJ, Wang JT. Lai MY, Chen DS. Blood-bank 
screening for hepatitis G. Lancet 1997; 349: 207. 
Sampietro M, Badalamenti S. Graziani G, et al. Hepatitis (; virus 
infection in hemodialysis patients. Kidney Int 1997; 51: 348-52. 
Shiiiiizu M. Sugiyama T, Kojinia M. Frequency o f  hepatitis GB 
virus C in patients on  maintenance heniodialysis. Nippon 
Kinsho 1997: 55: 545-8. 
Z h e l e z o v a  a n d  K a r a i v a n o v a :  GBV-C/HGV-is i t  a n o v e l  h u m a n  ' h e p a t i t i s '  v i r u s ?  68 1 
32. Cornu C, Jadoul M, Loute G, Goubau P. Hepatitis G virus 
infection in hemodialysed patients: epidemiology and clinical 
relevance. Nephrol Dialysis Transplant 1997; 12: 1326-9. 
33. Toyoda H ,  Fukuda Y, Hayakawa T. Hepatitis GB virus C 
infection in Japanese hemophiliacs with persistent hepatitis C 
virus infection. Nippon Kinsho 1997; 55: 554-8. 
34. Feucht HH,  Fischer L, Sterneck M, Knodler B, Broelsch CE, 
Laufi R. GB virus C infection and liver transplantation: 
increased risk of transfusion-transmitted infection. Blood 1997; 
35. Pessoa MG, Terrault NA, Ferrell LI3, et al. Hepatitis G virus in 
patients with cryptogenic liver disease undergoing liver 
transplantation. Hepatology 1997; 25: 1266-70. 
36. Murthy BV, Muerhoff AS, Desai SM, et al. GB hepatitis agent 
in cadaver organ donors and their recipients. Transplantation 
1997; 63: 346-51. 
37. Nakatsuji Y, Tanaka E, Kiyosawa K. Epidemiology of hepatitis 
G virus infection in Japan. Nippon Rinsho 1997; 55: 604-8. 
38. Sugai Y, Nakayama H.  HGBV-C infection in patients with 
chronic liver disease. Nippon Rinsho 1997; 55: 564-8. 
39. Alter MJ, Gallagher M, Morris TT, et al. Acute non-A-E 
hepatitis in the United States and the role of hepatitis G virus 
infection. N Engl J Med 1997; 336: 741-6. 
40. Hadziyannis SJ, Wages J. Kim JP, et al. Frequency ofviremia with 
a new hepatitis virus (GBV-C/HGV) in patients with liver 
disease and in groups at high risk of exposure to blood and blood 
products. J Hepatol 1995; 23(suppl 1): S78. 
41. Yoshiba M, Okamoto H, Mishiro S .  Detection of the GBV- 
C/HGV-C hepatitis virus genome in serum from patients with 
fulminant hepatitis of unknown aetiology. Lancet 1995; 346: 
42. Ishikawa K, Hasegawa K, Hayashi N.  GBV-C/HGV is rare but 
possible causative agent of non-A non-B fulminant hepatitis. 
Nippon Rinsho 1997; 55: 621-4. 
43. Heringlake S ,  Osterkamp S ,  Trautwein C, et al. Association 
between fulminant hepatic failure and a strain of GBV virus C. 
Lancet 1996; 348: 1626-9. 
44. Fischler B, Lara C, Chen M, Sonnerborg A, Nemeth A, Sallberg 
M. Genetic evidence for mother-to-infant transmission of 
hepatitis G virus. J Infect Dis 1997; 176: 281-5. 
45. Dawson GJ, Schlauder GG, Pilot-Matias TJ, et al. Prevalence 
studies of GB virus-C infection using reverse transcriptase- 
polymerase chain reaction. J Med Virol 1996; 50: 97-103. 
89: 2223-4. 
1131-2. 
46. Hwang SJ. Lu F W ,  Chan CY, Wang YJ, Wu JC, Lee SD. The 
role of hepatitis G virus infection in patients with acute post- 
transfusion hepatitis in Taiwan. Gastroenterology 1997; 112: 
47. Alter HJ. The cloning and clinical implications of GBV-C/HGV 
and HGBV-C. N Engl J Med 1996; 334: 1536-7. 
48. Guilera M, Saiz JC, Lopez-Labrador FX, et al. Hepatitis G virus 
infection in chronic liver disease. Gut 1998; 42: 107-1 1. 
49. Tanaca E, Alter HJ, Nakatsuji Y, et al. Effect of hepatitis G virus 
infection on chronic hepatitis C.  Ann Intern Med 1996; 125: 
50. Petrik J, Guella L, Wight DGD, et al. Hepatic histology in 
hepahtis C virus carriers coinfected with hepatitis G virus. Gut 
1998; 42: 1 0 3 4 .  
51. Bralet MF', Roudot-Thoraval F, Pawlotsky JM, et al. 
Histopathologic impact of GB virus C infection on chronic 
hepatitis C. Gastroenterology 1997; 112: 188-92. 
52. Inoue K, Yoshiba M, Sekiyama K. Causal relationship between 
GBV-C and fulminant hepatitis. Nippon Rinsho 1997; 55: 
53. Haydon GH, Jarvis LM, Simpson KJ, Hayes PC, Sinunonds P. 
The clinical significance of the detection of hepatitis GBV-C 
R N A  in the serum of patients with fulnlinant, presumed viral, 
hepatitis. J Viral Hepat 1997; 4: 45-9. 
54. Feucht HH,  Fischer L, Sterneck M, Broelsch CE, Laufs R. GB 
virus C transmission by blood products. Lancet 1997; 349: 435. 
55. Baba T, Makino R, Shibata M, Harada E, Mitamura K. 
Interferon treatment for hepatitis G virus infection in patients 
with chronic hepatitis C. Nippon Rinsho 1997; 55: 625-30. 
56. lkeda M, Sugiyama K, Mizutani T, Tanaca T, Shimotohno K, 
Kato N. Hepatitis G virus replication in human cultured cells 
displaying susceptibility to hepatitis C virus infection. Biochem 
Biophys Res Commun 1997; 235: 505-8. 
57. Karayiannis P, Hadziyannis SJ, k m  J, et al. Hepatitis G virus 
infection: clinical characteristics and response to interferon. J 
Viral Hepat 1997; 4: 37-44. 
58. Okamoto H. Hepatitis G virus (HGBV-C/GBV-C/HGV) as a 
putative agent for non-A to E hepatitis. Nippon Rinsho 1997; 
55: 515-22. 
1260-4. 
740-3. 
578-82. 
